Wegovy oral form sees weak demand in Germany one month post-launch

Novo Nordisk's oral Wegovy (semaglutide) has been available in Germany for a month, but pharmacists report low demand, contrasting with the high uptake of the injectable version. This suggests potential market saturation, reimbursement hurdles, or patient preference for injections, which could impact Novo Nordisk's revenue projections for the oral formulation.